Zur Kurzanzeige

2019-03-20Zeitschriftenartikel DOI: 10.25646/6170
Mucosal and cutaneous Human Papillomavirus seroprevalence among adults in the prevaccine era in Germany — Results from a nationwide population-based survey
dc.contributor.authorLoenenbach, Anna D.
dc.contributor.authorPoethko-Müller, Christina
dc.contributor.authorPawlita, Michael
dc.contributor.authorThamm, Michael
dc.contributor.authorHarder, Thomas
dc.contributor.authorWaterboer, Tim
dc.contributor.authorSchröter, Juliane
dc.contributor.authorDeleré, Yvonne
dc.contributor.authorWichmann, Ole
dc.contributor.authorWiese-Posselt, Miriam
dc.date.accessioned2019-05-29T07:19:11Z
dc.date.available2019-05-29T07:19:11Z
dc.date.issued2019-03-20none
dc.identifier.other10.1016/j.ijid.2019.03.022
dc.identifier.urihttp://edoc.rki.de/176904/6197
dc.description.abstractBackground Human Papillomavirus (HPV) vaccination of girls was introduced in Germany in 2007. However, data on the distribution of vaccine-relevant HPV types in the general population in Germany in the prevaccine era are limited. Methods Serum samples collected during the German National Health Interview and Examination Survey 1998 (GNHIES98), a nationally representative study including men and women aged 18–79 years, were tested for antibodies to 19 mucosal and cutaneous HPV types. Multivariable regression models were developed to identify associations between demographic and behavioral characteristics and HPV seropositivity. Results Of the 6517 serum samples tested, almost a quarter was seropositive for at least one of the nine HPV vaccine types with no clear age-pattern. HPV-6 and HPV-59 were the most common mucosal types, while HPV-1 and HPV-4 were the most common cutaneous HPV types. Factors independently associated with HPV-16 seroprevalence were seropositive to other sexually transmitted infections and lifetime number of sex partners, as well as urbanity (only among females). Conclusions Prevalence of naturally acquired antibodies to HPV types which can be prevented by vaccination is high in both sexes and all age groups. These data can serve as baseline estimates to evaluate the population-level impact of the current vaccination strategy.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectHuman papillomaviruseng
dc.subjectPrevalenceeng
dc.subjectSerologyeng
dc.subjectVaccineeng
dc.subjectGeneral populationeng
dc.subjectSeroepidemiologic studieseng
dc.subjectPredictorseng
dc.subjectGermanyeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleMucosal and cutaneous Human Papillomavirus seroprevalence among adults in the prevaccine era in Germany — Results from a nationwide population-based surveynone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6197-0
dc.identifier.doihttp://dx.doi.org/10.25646/6170
dc.type.versionpublishedVersionnone
local.edoc.container-titleInternational Journal of Infectious Diseasesnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.sciencedirect.com/science/article/pii/S1201971219301511none
local.edoc.container-publisher-nameElseviernone
local.edoc.container-volumeJune 2019none
local.edoc.container-issueVolume 83none
local.edoc.container-reportyear2019none
local.edoc.container-year2019none
local.edoc.container-firstpage3none
local.edoc.container-lastpage11none
local.edoc.rki-departmentInfektionskrankheitennone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige